ROBIN ISDELL: Open Payments
NPI 1518560655 · SUFFOLK, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$678 in 30 payments from 10 companies in 2025. Trend: 2023 $1,117 · 2024 $4,973 · 2025 $678
Food & beverage: $678
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $218 |
| Ardelyx, Inc. | 4 | $92 |
| Janssen Biotech, Inc. | 4 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $72 |
| Celltrion USA Inc. | 2 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Ipsen Biopharmaceuticals, Inc | 1 | $25 |
| Novo Nordisk Inc | 1 | $21 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $20 |
Products named: IBSRELA, SKYRIZI, TREMFYA, DUPIXENT, VEGZELMA, ENTYVIO, LINZESS, RINVOQ.
Industry payments across VA — which companies pay providers there.
